{"entity":{"id":"nikang-therapeutics","kind":"company","name":"NiKang Therapeutics","aka":["NiKang Therapeutics, Inc.","Nikang Therapeutics"],"tldr":"A US company making pills that block or break down cancer-driving proteins. Its drugs are in early trials for kidney cancer, liver cancer, hormone-receptor-positive breast cancer and other solid tumours.","summary":"NiKang Therapeutics develops small molecules for oncology targets, using structure-based drug design. NKT2152 is an oral HIF2-alpha inhibitor tested in a Phase 1/2 study in advanced clear cell renal cell carcinoma (NCT05119335, now terminated) and, in collaboration with Roche, with atezolizumab and bevacizumab in first-line hepatocellular carcinoma in the MORPHEUS-Liver platform study. NKT3964 is an oral CDK2 PROTAC degrader in a Phase 1 study in advanced solid tumours (NCT06586957), now enrolling CCNE1-amplified endometrial cancer, and NKT5097 is an oral CDK2/CDK4 dual degrader in a Phase 1 study alone and with endocrine therapy in HR-positive, HER2-negative breast cancer (NCT07029399). The company's timeline states it was incorporated in July 2017 and raised a $10 million Series A (December 2017), a $50 million Series B (September 2020) and a $200 million Series C (May 2021), and lists collaborations with Erasca (SHP2), Pfizer, Hansoh and Roche (HIF2).","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://www.nikangtx.com/"},{"label":"Science and pipeline page","url":"https://www.nikangtx.com/science-and-pipeline/"},{"label":"About us and company timeline","url":"https://www.nikangtx.com/about-us/"},{"label":"RA Capital portfolio entry","url":"https://www.racap.com/portfolio/nikang-therapeutics"}],"tags":[],"related":[],"cancers":["clear-cell-rcc","hcc","breast-hr-positive","endometrial"],"sections":["targeted-therapy"],"technologies":["protac-degrader"],"targets":["hif2a","cdk2"],"drugs":["nkt2152","nkt3964","nkt5097"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The company's pipeline page cites MORPHEUS-Liver as NCT04524781, which the ClinicalTrials.gov API does not find; the MORPHEUS-Liver study that includes NKT2152 is NCT04524871 (sponsor Hoffmann-La Roche, in OnCo as nct04524871). It is not linked here because NiKang is not the sponsor.","NCT05119335 and NCT05935748 (NKT2152, both terminated), NCT06586957 and NCT07029399 were confirmed through the ClinicalTrials.gov v2 API; none is a trial record in OnCo yet.","CDK4 is not linked separately because OnCo holds only a combined CDK4/6 target."],"hq":"Wilmington, DE","country":"US","companyType":"biotech","website":"https://www.nikangtx.com/","founded":2017,"stage":"startup","investors":["ra-capital"],"funding":[{"round":"Series A","year":2017,"amountUsd":10000000,"source":"https://www.nikangtx.com/about-us/"},{"round":"Series B","year":2020,"amountUsd":50000000,"source":"https://www.nikangtx.com/about-us/"},{"round":"Series C","year":2021,"amountUsd":200000000,"source":"https://www.nikangtx.com/about-us/"}]},"route":"/companies/nikang-therapeutics/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"target":[{"id":"cdk2","kind":"target","name":"CDK2","route":"/targets/cdk2/"},{"id":"hif2a","kind":"target","name":"HIF-2α","route":"/targets/hif2a/"}],"drug":[{"id":"nkt2152","kind":"drug","name":"NKT2152","route":"/drugs/nkt2152/"},{"id":"nkt3964","kind":"drug","name":"NKT3964","route":"/drugs/nkt3964/"},{"id":"nkt5097","kind":"drug","name":"NKT5097","route":"/drugs/nkt5097/"}],"company":[{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"}],"trial":[{"id":"nct05119335","kind":"trial","name":"A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma","route":"/trials/nct05119335/"},{"id":"nct06586957","kind":"trial","name":"A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors","route":"/trials/nct06586957/"},{"id":"nct07029399","kind":"trial","name":"A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors","route":"/trials/nct07029399/"},{"id":"nct05935748","kind":"trial","name":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","route":"/trials/nct05935748/"}]}}